Literature DB >> 17295810

Flat adenomas.

Doug Speake1, Deepak Biyani, Frank A Frizelle, Angus J M Watson.   

Abstract

This article was presented at the conjoint CSSA and RACS (colorectal section) spring meeting Queensland, Australia, September 2004. The adenoma-carcinoma sequence describes a succession of events from polypoid adenoma to colorectal cancer. However, this model only accounts for up to two-thirds of colorectal cancers. There is growing evidence that flat adenomas are precursor lesions to a flat type of colorectal cancer and certain subtypes of these polyps are at greater risk of malignant transformation. If confirmed, the implications for screening, endoscopic recognition and management will become of increasing importance if we are to decrease the incidence of colorectal cancer.

Entities:  

Mesh:

Year:  2007        PMID: 17295810     DOI: 10.1111/j.1445-2197.2006.03847.x

Source DB:  PubMed          Journal:  ANZ J Surg        ISSN: 1445-1433            Impact factor:   1.872


  5 in total

Review 1.  Endoscopy and polyps-diagnostic and therapeutic advances in management.

Authors:  Scott R Steele; Eric K Johnson; Bradley Champagne; Brad Davis; Sang Lee; David Rivadeneira; Howard Ross; Dana A Hayden; Justin A Maykel
Journal:  World J Gastroenterol       Date:  2013-07-21       Impact factor: 5.742

2.  Putative precursor cancer cells in human colorectal cancer tissue.

Authors:  Teodora E Goranova; Masayuki Ohue; Kikuya Kato
Journal:  Int J Clin Exp Pathol       Date:  2008-07-14

3.  Hypermethylated SFRP2 gene in fecal DNA is a high potential biomarker for colorectal cancer noninvasive screening.

Authors:  Dao-Rong Wang; Dong Tang
Journal:  World J Gastroenterol       Date:  2008-01-28       Impact factor: 5.742

Review 4.  Murine models of colorectal cancer.

Authors:  Joshua M Uronis; David W Threadgill
Journal:  Mamm Genome       Date:  2009-05-15       Impact factor: 2.957

Review 5.  Current concepts in colorectal cancer prevention.

Authors:  Patricia A Thompson; Eugene W Gerner
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2009-08       Impact factor: 3.869

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.